A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93 percent of pediatric patients tested, researchers at UT Southwestern’s Simmons Cancer Center announced. The research was published in March 2018 in The Lancet Oncology.
Evelyn, called Evie by her family, is a bubbly toddler who loves superheroes and princesses. During her 1-year checkup, her doctor had trouble getting a good reading on her vision. Ten days after being diagnosed with retinoblastoma, she began treatment.